Scientists have developed new light-sensitive chemicals that can radically improve the treatment of aggressive cancers with ...

TheraBionic is the only FDA-approved therapy indicated in liver cancer patients that fail first-line and second-line therapy, so that's really the place it takes right now in 2025. Patients can ...

A new nanomedicine drug delivery system improves chemotherapy targeting for choriocarcinoma, shrinking tumors by 95% in mouse models. Researchers engineered polymersomes to enhance methotrexate (MTX) ...

15, 2025 — In patients with high-risk HER2-positive breast cancer, post-surgery, or adjuvant, treatment with trastuzumab ... abnormal patches and plaques). It affects about 2% of the population ...

One of cancer’s deadliest tricks is its ability to spread to other organs. An existing cardiac drug has now been found to reduce the risk of metastasis by dissolving circulating clusters of breast ...

The U.S. Food and Drug Administration announced last week that a pharmaceutical company is removing a fentanyl patch from ...

A Keighley hospital has become the first in the North to pilot a new app to support cancer patients. For the next 14 months ...

Psoriasis is a chronic skin disease that manifests itself mainly with skin symptoms (dryness, itching, scaly skin, abnormal patches and plaques). It affects about 2% of the population and is mediated ...

Psoriasis is a chronic skin disease that manifests itself mainly with skin symptoms (dryness, itching, scaly skin, abnormal ...

The Marquie Group, Inc. (OTCMKTS: TMGI) is proud to announce a strategic shift in its Simply Whim subsidiary, refocusing the Whim brand on products designed specifically for cancer patients. Following ...

In "remarkable" work, a patch of engineered heart muscle cells was used to strengthen a patient's heart before transplant.

which two-thirds of all cancer patients will receive at some point in their treatment journey. Typically delivered through administering a beam of X-rays or other particles over the course of two ...